N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide trifluoroacetic acid | 1228652-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide trifluoroacetic acid
• 英文别名: N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide trifluoroacetate；N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethylbenzamide trifluoroacetate；N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide TFA salt；N-[2-(azetidin-3-ylamino)-2-oxoethyl]-3-(trifluoromethyl)benzamide;2,2,2-trifluoroacetic acid
• CAS: 1228652-98-9
• 化学式: C₂HF₃O₂*C₁₃H₁₄F₃N₃O₂
• 分子量: 415.292
• InChiKey: CBDYGSAWLDTVJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide trifluoroacetic acid 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 生成 N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide
  参考文献：
  名称：

  4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

  摘要：

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。

  公开号：

  US20100267689A1
• 作为产物：
  描述：

  间三氟甲基马尿酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide trifluoroacetic acid
  参考文献：
  名称：

  Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists

  摘要：

  A series of 4-azetidinyl-1-aryl-cyclohexanes as potent CCR2 antagonists with high selectivity over activity for the hERG potassium channel is discovered through divergent SARs of CCR2 and hERG. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.080

文献信息

• 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267689A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267668A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100144695A1

  公开（公告）日：2010-06-10

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

  本发明涉及式（I）的化合物。其中：R1、R2、R3和R4如规范中所定义。该发明还涉及包含式（I）化合物的药物组合物，以及通过给予式（I）化合物来预防、治疗或改善CCR2介导的综合症、疾病或疾病的方法，例如II型糖尿病、肥胖或哮喘。
• 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2
  申请人：Zhang Xuqing

  公开号：US08513229B2

  公开（公告）日：2013-08-20

  The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及公式（I）的化合物：其中：X，R1，R2，R3和R4如规范中所定义。该发明还涉及一种预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病是2型糖尿病、肥胖症和哮喘。该发明还涉及一种通过给哺乳动物以公式（I）中至少一种化合物的治疗有效量来抑制CCR2活性的方法。
• Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists
  作者：Xuqing Zhang、Heather Hufnagel、Thomas Markotan、James Lanter、Chaozhong Cai、Cuifen Hou、Monica Singer、Evan Opas、Sandra McKenney、Carl Crysler、Dana Johnson、Zhihua Sui

  DOI：10.1016/j.bmcl.2011.06.080

  日期：2011.9

  A series of 4-azetidinyl-1-aryl-cyclohexanes as potent CCR2 antagonists with high selectivity over activity for the hERG potassium channel is discovered through divergent SARs of CCR2 and hERG. (C) 2011 Elsevier Ltd. All rights reserved.